Secondulfo C, Visco V, Virtuoso N, Fortunato M, Migliarino S, Rispoli A
Life (Basel). 2024; 14(5).
PMID: 38792638
PMC: 11123235.
DOI: 10.3390/life14050617.
Brandenburg V, Ketteler M
Nutrients. 2022; 14(15).
PMID: 35893866
PMC: 9330693.
DOI: 10.3390/nu14153009.
Pirklbauer M, Bushinsky D, Kotanko P, Schappacher-Tilp G
Front Med (Lausanne). 2021; 8:704970.
PMID: 34595186
PMC: 8477020.
DOI: 10.3389/fmed.2021.704970.
Schappacher-Tilp G, Cherif A, Fuertinger D, Bushinsky D, Kotanko P
Physiol Rep. 2019; 7(7):e14045.
PMID: 30927339
PMC: 6440916.
DOI: 10.14814/phy2.14045.
Zheng C, Wu C, Hung C, Liao M, Shyu J, Hsu Y
Nutrients. 2018; 10(2).
PMID: 29439405
PMC: 5852772.
DOI: 10.3390/nu10020196.
Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism.
Ribeiro C, Penido M, Guimaraes M, Tavares M, Souza B, Leite A
World J Nephrol. 2016; 5(5):437-47.
PMID: 27648407
PMC: 5011250.
DOI: 10.5527/wjn.v5.i5.437.
Molecular pathways associated with transcriptional alterations in hyperparathyroidism.
Lee F, Lee J, Jan W, Wu C, Chen H, Cheng S
Oncol Lett. 2016; 12(1):621-626.
PMID: 27347190
PMC: 4907271.
DOI: 10.3892/ol.2016.4623.
EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.
Hemetsberger M, Oberbauer R, Erb H, Pronai W
Wien Med Wochenschr. 2015; 165(19-20):410-8.
PMID: 26302869
DOI: 10.1007/s10354-015-0379-0.
Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects.
Martin K, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P
Nephrol Dial Transplant. 2013; 29(2):385-92.
PMID: 24235081
PMC: 3910343.
DOI: 10.1093/ndt/gft417.
Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.
Miller G, Davis J, Shatzen E, Colloton M, Martin D, Henley C
Nephrol Dial Transplant. 2011; 27(6):2198-205.
PMID: 22036941
PMC: 3363978.
DOI: 10.1093/ndt/gfr589.
Treatment of secondary hyperparathyroidism in kidney disease: what we know and do not know about use of calcimimetics and vitamin D analogs.
Wetmore J, Quarles L
Int J Nephrol Renovasc Dis. 2011; 1:5-17.
PMID: 21694914
PMC: 3108756.
DOI: 10.2147/ijnrd.s4368.
Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism.
Komaba H, Nakanishi S, Fujimori A, Tanaka M, Shin J, Shibuya K
Clin J Am Soc Nephrol. 2010; 5(12):2305-14.
PMID: 20798251
PMC: 2994093.
DOI: 10.2215/CJN.02110310.
The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.
Henley C, Davis J, Miller G, Shatzen E, Cattley R, Li X
Eur J Pharmacol. 2009; 616(1-3):306-13.
PMID: 19470383
PMC: 6854701.
DOI: 10.1016/j.ejphar.2009.05.013.
Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism.
Meola M, Petrucci I, Barsotti G
Nephrol Dial Transplant. 2009; 24(3):982-9.
PMID: 19181759
PMC: 2644631.
DOI: 10.1093/ndt/gfn654.
Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?.
Wetmore J, Quarles L
Nat Clin Pract Nephrol. 2008; 5(1):24-33.
PMID: 18957950
PMC: 3924719.
DOI: 10.1038/ncpneph0977.
Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of parathyroid glands in refractory uremic hyperparathyroidism?.
Lomonte C, Vernaglione L, Chimienti D, Bruno A, Cocola S, Teutonico A
Clin J Am Soc Nephrol. 2008; 3(3):794-9.
PMID: 18322048
PMC: 2386693.
DOI: 10.2215/CJN.04150907.
